Questionnaire Administration for Diabetes Mellitus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
City of Hope Medical Center, Duarte, CA
Diabetes Mellitus+3 More
Questionnaire Administration - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This clinical trial tests the Eat, Move, Live (EML) Program in reducing the risk of chronic diseases among underserved communities by improving healthy lifestyle practices, increasing physical activity and encouraging healthy eating behaviors. EML is a series of free culturally and linguistically appropriate nutrition and physical activity sessions. The interactive education segment of the EML Program is culturally responsive, and based on the community EML program, and topics will include: nutrition guidelines, reading food labels, recipe modification and healthy food preparation, eating healthy on a budget, chronic diseases information and prevention strategies. The EML program may help reduce the risk of cancer and chronic diseases by encouraging more physical activity and healthy eating behaviors.

Eligible Conditions

  • Diabetes Mellitus
  • Malignant Neoplasms

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

15 Primary · 0 Secondary · Reporting Duration: Baseline to 12 weeks

Baseline and week 12
Changes in attitudes and beliefs as measured by questionnaires from baseline to week 12
Changes in behavior as measured by questionnaires from baseline to week 12
Baseline to 12 weeks
Changes in biomarkers
Changes in body fat percentage from baseline to week 12
Changes in chest circumference from baseline to week 12
Changes in diastolic blood pressure from baseline to week 12
Changes in height from baseline to week 12
Changes in hip circumference from baseline to week 12
Changes in left upper arm circumference from baseline to week 12
Changes in left upper thigh circumference from baseline to week 12
Changes in right upper arm circumference from baseline to week 12
Changes in right upper thigh circumference from baseline to week 12
Changes in systolic blood pressure from baseline to week 12
Changes in waist circumference from baseline to week 12
Changes in weight from baseline to week 12

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Supportive care (EML program)
1 of 1
Experimental Treatment

500 Total Participants · 1 Treatment Group

Primary Treatment: Questionnaire Administration · No Placebo Group · N/A

Supportive care (EML program)Experimental Group · 2 Interventions: Questionnaire Administration, Behavioral Intervention · Intervention Types: Other, Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Behavioral Intervention
2017
Completed Phase 4
~3220

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 12 weeks
Closest Location: City of Hope Medical Center · Duarte, CA
Photo of Duarte 1Photo of Duarte 2Photo of Duarte 3
2002First Recorded Clinical Trial
7 TrialsResearching Diabetes Mellitus
142 CompletedClinical Trials

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
12,930 Previous Clinical Trials
41,293,960 Total Patients Enrolled
10 Trials studying Diabetes Mellitus
176,156 Patients Enrolled for Diabetes Mellitus
City of Hope Medical CenterLead Sponsor
501 Previous Clinical Trials
2,245,895 Total Patients Enrolled
7 Trials studying Diabetes Mellitus
244 Patients Enrolled for Diabetes Mellitus
Victoria L SeewaldtPrincipal InvestigatorCity of Hope Medical Center

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You agree to group consent at week 1.\n
You are able to speak and understand English and/or Spanish.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.